CH-ACM-01 (Efficacy and safety of oral octreotide for acromegaly; ClinicalTrials.gov identifier: NCT01412424), the first phase III trial (a single-arm, open-l abel study) aimed to test the efficacy and safety of OOC, was conducted in 151 patients with complete or partially controlled acromegaly (IGF-1 <1.3 the upper limit of normal (ULN) for age and an integrated GH response over 2 h of <2.5 ng/mL).19 The patients had received a stable dose of injectable SRL for at least 3 months. Here, GH1 is linked to acromegaly.